Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects

Indian Journal of Physiology and Pharmacology

Volumn 52, Issue 1, 2008, Pages 53-63

  De, Shantanu ^a   Jain, Raka ^a   Ray, Rajat ^a   Dhawan, Anju ^a   Varghese, Sunny T ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Buprenorphine; Craving; Maintenance treatment; Plasma level

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; CANNABIS; CHLORPHENIRAMINE MALEATE; PENTAZOCINE; PLACEBO;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; EUPHORIA; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MORNING DOSAGE; OPIATE ADDICTION; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; STEADY STATE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WELLBEING; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; CHROMATOGRAPHY, THIN LAYER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUPHORIA; HEROIN DEPENDENCE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; NARCOTIC ANTAGONISTS; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 44949251043     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ray R. South Asia drug demand reduction report. UNDCP, ROSA: New Delhi. 2000.
2. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug and Alcohol Dependence 2005; 77: 71-79.
3. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology and Therapeutics 1994; 55: 569-580.
4. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry 1997: 54: 713-720.
5. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 1996; 53: 401-407.
6. Ling W, Charuvastra C, Collins JF, Batki S, Brown Jr LS, Kintaudi P, Wesson DR, McNicholas L, Tussel DJ, Malkernekar U, Renner JR, Santos E, Casadonte P, Fye C, Stine S, Wang RIH, Segal D. Buprenorphine maintenance treatment of opioid dependence: amulticentre randomized clinical trial. Addiction 1998; 93: 475-486.
7. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, Pezawas L, Aschauer HN, Kasper H. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94: 1337-1347.
8. Lin KM, Finder E. Neuroleptic dosage for Asians. American Journal of Psychiatry 1983; 140: 490-491.
9. Jain R. Detection of drugs of abuse in body fluids - a manual for laboratory personnel. National Drug Dependence Treatment Centre, AIIMS: New Delhi. 1990.
10. Martinez D, Jurado MC, Ropetto M. Analysis of buprenorphine in plasma and urine by gas chromatography. Journal of Chromatography 1990; 528: 459-463.
11. Handelsman L, Cochrane KJ, Aronson JM, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. American Journal of Drug Abuse 1987; 13: 293-308.
12. Haertzen CA, Hickey JE. Addiction Research Centre Inventory (ARCI): measurement of euphoria and other drug effects. In: Methods of assessing the reinforcing properties of abused drugs. Bozarth MA (Ed). Springer Verlag: New York USA 1987; 489-524.
13. Jasinski DR Opiate withdrawal syndrome: acute and protracted aspects. Annals of New York Academy of Science 1978; 363: 183-186.
14. Folstein MF, Luria R. Reliability, validity and clinical application of the visual analog scale. Psychological Medicine 1973; 3: 479-486.
15. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug and Alcohol Dependence 2004; 15: 37-45.
16. Strain EC, Stitzer ML, Liebson LA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 1994; 151: 1025-1030.
17. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. Journal of Substance Abuse Treatment 2003; 24: 217-220.
18. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. British Journal of General Practice 2005; 55: 139-146.
19. Hiltunen AJ, Lafolie P, Martel J, Ottosson EC, Boreus LO, Beck O, Borg O, Hjemdahl P. Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychopharmacology 1995; 118: 122-136.
20. Smith CM. The pharmacology of sedative/hypnotics, alcohol and anaesthetics. In: Martin RW (Ed). Drug Addiction. Vol. 1, Springer-Verlag, Berlin Heidelberg New York, 1977.
21. Weinstein A, Wilson S, Bailey J, Myles J, Nutt D. Imagery of craving in opiate addicts undergoing detoxification. Drug and Alcohol Dependence 1997; 48: 25-31.
22. Childress AR, McLellan AT, O'Brien CP. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. British Journal of Addiction 1986; 81: 655-660.
23. Marlatt GA. Cue exposure and relapse prevention in the treatment of addictive behaviours. Addictive Behaviors 1990; 15: 395-399.
24. Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug and Alcohol Dependence 1999; 55: 157-163.
25. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disorders 1993; 181: 358-364.